Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

The GSK oncology products it has sold on to Novartis were worth approximately $2 billion in 2014, having posted a growth of around 32 per cent compared to the previous year. The drugs include ...

Full Year 2024 Results Key Financial Results Revenue: UK£31.4b (up 3.5% from FY 2023). Net ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.